Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 15, 2018
Distillery Therapeutics

Infectious disease

BioCentury | Nov 18, 2013
Clinical News

AERAS-456: Phase I/IIa started

BioCentury | Jan 16, 2012
Clinical News

Tuberculosis vaccine: Phase II started

BioCentury | Feb 17, 2011
Targets & Mechanisms

Protecting against latent TB

BioCentury | Feb 3, 2011
Distillery Therapeutics

Indication: Infectious disease

BioCentury | Mar 12, 2009
Distillery Therapeutics

Indication: Infectious disease

BioCentury | Mar 5, 2009
Targets & Mechanisms

Subunit boost for TB vaccines

BioCentury | Dec 10, 2007
Clinical News

HyVac4: Phase I started

BioCentury | Mar 19, 2007
Clinical News

Tuberculosis: Preliminary Phase I data

Items per page:
1 - 10 of 10